CLDN6 expression seems ubiquitous in all elements of GCT and is worthy of investigation as a diagnostic biomarker and therapeutic target. (Clinical trial information: NCT03760081).

2 years ago

P2 data • Journal

CLDN6 (Claudin 6)

CLDN6 expression • CLDN6 positive

ASP1650

3years

Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR) (clinicaltrials.gov)

P1, N=42, Completed, Ganymed Pharmaceuticals GmbH | N=72 --> 42

3 years ago

Clinical • Enrollment change

MUC16 (Mucin 16, Cell Surface Associated) • CLDN6 (Claudin 6)

ASP1650

4years

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors (clinicaltrials.gov)

P2, N=19, Completed, Astellas Pharma Global Development, Inc. | Recruiting --> Completed | N=46 --> 19 | Trial completion date: Feb 2021 --> Oct 2020 | Trial primary completion date: Feb 2021 --> Oct 2020

4 years ago

Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date

AFP (Alpha-fetoprotein)

ASP1650

4years

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors (clinicaltrials.gov)

P2, N=46, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Oct 2022 --> Feb 2021 | Trial primary completion date: Sep 2022 --> Feb 2021

4 years ago

Clinical • Trial completion date • Trial primary completion date

AFP (Alpha-fetoprotein)

ASP1650

over4years

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors (clinicaltrials.gov)

P2, N=46, Recruiting, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Recruiting

over 4 years ago

Clinical • Enrollment open

AFP (Alpha-fetoprotein)

ASP1650